Multiple Myeloma News


Here are all the latest news articles written by The Beacon's staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Farydak (panobinostat), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), melflufen, MOR202, oprozomib, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.


[ by | Jun 1, 2015 7:55 pm | 4 Comments ]
ASCO 2015 Multiple Myeloma Update – Poster Presentations: Current Therapies; Impact Of Del(17p) And T(11;14)

A poster session yesterday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting was the venue for the first substantial dose of multiple myeloma-related presentations at the conference.

During the session, research results were made available for review by meeting attendees in the form of posters, each of which summarized the results of a single study. As is typically the case during such sessions, each poster was about two feet high by three or four feet in length. All posters were displayed throughout a large conference hall.

Most …

Read the full story »
[ by | Updated: Jun 3, 2015 10:20 am | 2 Comments ]
Daratumumab Continues To Show Substantial Promise As Potential New Treatment For Multiple Myeloma (ASCO 2015)

Updated results of a key Phase 1/2 trial testing the potential new myeloma ther­a­py daratumumab were released this morning. The new results confirm previous research indicating that single-agent daratumumab has notable activity as a multiple myeloma therapy.

Specifically, the results show that nearly one third of the trial participants – who had received a median of five prior therapies – responded to single-agent dara­tumumab. The median time to disease progression was 3.7 months, and the esti­mated one-year overall survival rate was 65 percent.

Daratumumab’s safety profile in the …

Read the full story »
[ by | May 29, 2015 11:52 pm | 2 Comments ]
Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2015)

The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier today, May 29, and will go through June 2 in Chicago.

Approximately 30,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss current research in cancer treat­ment and care.

During the meeting, there will be pre­sen­ta­tions about all types of cancer, in­clud­ing many pre­sen­ta­tions focused specifically on multiple myeloma. In fact, more than 90 myeloma-related studies are scheduled to be pre­sented, in one form or another, in connection …

Read the full story »
[ by | Apr 20, 2015 5:59 pm | 3 Comments ]
Subcutaneous Velcade Leads To Similar Response Rates, But Fewer Side Effects, Compared To IV Velcade In Newly Diagnosed Multiple Myeloma

Initial results of a German clinical trial confirm pre­vi­ous find­ings that sub­cu­ta­ne­ous (under-the-skin) injections of Velcade for the treat­ment of myeloma lead to fewer side effects – but similar overall response rates – com­pared to intra­ve­nous (IV) infusions of the drug.

The trial results also indicate, however, that IV adminis­tra­tion of Velcade may lead to deeper treat­ment responses when patients are given the drug for a limited number of treat­ment cycles.

The German trial is notable not just because it is the largest study to date that has directly compared sub­cu­ta­ne­ous and …

Read the full story »
[ by | Apr 7, 2015 6:43 pm | One Comment ]
Combination Of Farydak And High-Dose Kyprolis Effective In Relapsed Multiple Myeloma

The results of a small Phase 1/2 clinical trial suggest that a com­bi­na­tion of Farydak and high-dose Kyprolis is effective as a treat­ment for relapsed multiple myeloma.

Participants in the trial were heavily pretreated, having had a median of five previous myeloma ther­a­pies. More than 70 per­cent of the patients, however, had at least a partial re­sponse to the trial regi­men at the target doses established during the trial’s first phase. The estimated two-year overall survival rate among the patients was 67 percent.

A response rate of more than 70 …

Read the full story »
[ by | Mar 31, 2015 5:22 pm | 12 Comments ]
Survival Of Nonsecretory Multiple Myeloma Patients Improves Over Last Decade

Results of a recent retrospective study conducted at the Mayo Clinic in­di­cate that the survival of patients with non­se­cre­tory multiple myeloma has improved over the last decade.

Nonse­cre­tory multiple myeloma is a rare form of myeloma in which a patient’s disease cannot be diagnosed or tracked by the presence of monoclonal protein in the blood or urine.  This is not the case for most myeloma patients, who have “se­cre­tory” disease which can be tracked using lab results such as a patient’s “M-spike” or free light chain levels.

The authors of …

Read the full story »